From antisense RNA to RNA modification: Therapeutic potential of RNA‐based technologies

Abstract

Therapeutic oligonucleotides interact with a target RNA via Watson‐Crick complementa-rity, affecting RNA‐processing reactions such as mRNA degradation, pre‐mRNA splicing, or mRNA translation. Since they were proposed decades ago, several have been approved for clinical use to correct genetic mutations. Three types of mechanisms of action (MoA) have emerged: RNase H‐ dependent degradation of mRNA directed by short chimeric antisense oligonucleotides (gapmers), correction of splicing defects via splice‐modulation oligonucleotides, and interference of gene expression via short interfering RNAs (siRNAs). These antisense‐based mechanisms can tackle several genetic disorders in a gene‐specific manner, primarily by gene downregulation (gapmers and siR‐ NAs) or splicing defects correction (exon‐skipping oligos). Still, the challenge remains for the repair at the single‐nucleotide level. The emerging field of epitranscriptomics and RNA modifications shows the enormous possibilities for recoding the transcriptome and repairing genetic mutations with high specificity while harnessing endogenously expressed RNA processing machinery. Some of these techniques have been proposed as alternatives to CRISPR‐based technologies, where the exogenous gene‐editing machinery needs to be delivered and expressed in the human cells to gen-erate permanent (DNA) changes with unknown consequences. Here, we review the current FDA-approved antisense MoA (emphasizing some enabling technologies that contributed to their suc-cess) and three novel modalities based on post‐transcriptional RNA modifications with therapeutic potential, including ADAR (Adenosine deaminases acting on RNA)‐mediated RNA editing, targeted pseudouridylation, and 2′‐O‐methylation.